stem cells differential gene expression and cell fate why manipulate stem cells?
DESCRIPTION
Stem cells Differential gene expression and cell fate Why manipulate stem cells? Potential sources of therapeutic cells Concluding thoughts. pluripotent stem cell. pluripotent stem cell. committed cell. pluripotent - having the potential to develop into any cell type of the body. - PowerPoint PPT PresentationTRANSCRIPT
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cellsV. Concluding thoughts
pluripotent stem cell
pluripotent stem cell committed cell
pluripotent- having the potential to develop into any cell type of the body
http://departments.weber.edu/chfam/prenatal/blastocyst.html
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cellsV. Concluding thoughts
Genes are made of DNA
DNA is within the nucleus of each of our cells.
This DNA is identical in each of the cells of our bodies…
…even though different cells have very different structures and functions
Q: How do cells with identical genetic compositions become so different from one another?
A: Different cells express different subsets of their genes.
Gene A Gene B Gene A Gene B
In neurons, gene A is expressed but not gene B:
In muscle cells, gene B is expressed but not gene A:
Gene A Gene B
(muscle cell specific transcription factors)
(promoter of gene B)
In muscle cells, gene B is expressed because muscle cells have transcription factors that bind to gene B’s promoter.
Gene A Gene B
In muscle cells, gene B is expressed because muscle cells have transcription factors that bind to gene B’s promoter.
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cellsV. Progress on stem cell therapeutics
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
Bone marrow contains Hematopoetic Stem Cells
irradiation
(injection with bone marrow)
Adult stem cell types that have been tested clinically
Hematopoetic stem cellsMesenchymal stem cellsNeural stem cellsAdipose stem cells
Lin et al., 2013
Lin, et al., 2013
Most stem cell clinical trials have used adult stem cells
Adult Stem Cell Therapies
pros
cons
• no ethical dilemmas• autologous (self) donations are possible• cells need not be manipulated or grown in culture• no risks of teratomas (tumors)
• few tissues are represented by adult stem cells• those tissues that DO have them have very few• if not autologous, MUST be tissue type matched• evidence of clinical efficacy limited to HSCs• cannot be amplified or maintained in culture
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
http://departments.weber.edu/chfam/prenatal/blastocyst.html
Deb and Sarda, 2008
Animal Models in which hESC-Derived Cells have been Effective
2009-2011 Geron Corporation hESC-derived oligodendrocyte progenitors for treatment of spinal cord injuries (Daley, 2012)
-in animal models, these cells car repair damaged neurons-the first hESC clinical study to overcome FDA restrictions-four patients enrolled-no publications yet; no reported negative effects, but
unclear if treatments were effective
Clinical Trials using hESCs
2009-present Advanced Cell Technology (ACT) hESC-derived retinal pigment epithelial cells are being used to treat macular degeneration (Schwartz,et al. 2012)
-started with 2 patients, both showed vision improvement and no signs of tumors after 4 months
-study is continuing with higher doses of cells and in more patients
Clinical Trials using hESCs, cont.
ESCs from IVF
pros
cons
• source tissue plentiful• cells divide infinitely in culture• easily programmable cells
• immune response problems• ethical controversy• tumor risks
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cells
1. issues with iPSCs2. progress with iPSCs
D. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
Takahashi and Yamanaka 2006
• DNA inserted randomly could create problems with endogenous DNA.• DNA insertions are inherited by all progeny of manipulated cell.• The genes added could cause cells to be more prone to division.
New iPSC protocols do NOT require insertion of foreign DNA
• Exposure of differentiated cells to chemical treatments caused them to become pluripotent (Masuda et al., 2013).
• Protein transduction of somatic cells can produce iPS cells (Nemes et al., 2013).
• Mouse lymphocytes were induced to become pluripotent via acid treatment (Obokata et al., 2014).
Stadtfield & Hochedlinger 2010
With iPSCs, the pluripotency must be tested
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cells
1. issues with iPSCs2. progress with iPSCs
D. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
Many cell types have been derived from human iPS cells
• hepatocytes (Takebe et al., 2014)• neurons (Prilutsky et al, 2014)• folliculogenic stem cells (Yang et al., 2014)• cardiomyocytes (Seki et al., 2014)• pancreatic beta cells (Thatava et al, 2011)
First iPSC clinical trial to begin this year
• lab of Dr. Masayo Takahashi at Riken in Kobe, Japan
• 6 patients with macular degeneration in trial
• iPSCs will be reprogrammed in culture to become retinal pigment epithelium
• once 50,000 cells per patient are produced, these will be introduced back into the retinas
Grskovic, et al. 2011
Successful “disease in a dish” models
• Familial dysautonomia, a genetic disease of autonomic nervous system
• Rett Syndrome, a disease within the autism spectrum
• HGPS (progeria), premature aging
• Parkinson’s, degradation of midbrain dopaminergic neurons leading to loss of motor activity
Grskovic, et al. 2011
iSPCs
pros
cons
• patient-derived pluripotent cells• once established, cells divide infinitely in culture• easily programmable cells• less ethical controversy than ESCs• produce excellent tools for studying disease
• cells require a lot of manipulation to become iSPC • evidence of immunogenicity of iPSCs (Fu, 2013)• low rate of induced pluripotency (~.2%)• tumor risks
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
Freeman, 2012
ESCs from SCNT
pros
cons
• cells divide infinitely• easily programmable cells• genetically identical to patient• great for disease modeling
• ethical controversy• will require oocyte donors• not tested much with human cells
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
Transdifferentiation
Graf, 2011
Graf, 2011
I. Stem cellsII. Differential gene expression and cell fateIII. Why manipulate stem cells?IV. Potential sources of therapeutic cells
A. Adult stem cellsB. Embryonic stem cells (IVF embryos)C. Induced pluripotent stem cellsD. Embryonic stem cells (SCNT-derived)E. Transdifferentiation
V. Concluding thoughts
ESCs iPSCs
embryos
high
high
good
good
somatic cells
very high
some?
good
good
derivation
cancer risk
immunogenicity
growth in culture
ability to program
ESCs are currently considered the “gold standard” for pluripotency.
Current research is investigating whether iPSCs are truly equivalent to ESCs.
Many scientists developing iPSCs still must use ESCs for comparison in their experiments.
macular degenerationParkinson’sType II DiabetesAltzheimer’sheart diseasespinal cord injuriesburnsHuntington’s
Conditions that might be alleviated using stem-cell derived transplantations (a partial list)
cancer risk from cultured cells
immune response from cultured cells
creating cultured cells to have all the functions of those cells produced by the body
the necessity of producing a LOT of the target cells in culture
creating cultured cells that integrate with host tissues
Challenges to cell culture-derived transplantations
useful as a way to test drugs without experimenting on patients
a means to generate therapies specific to specific patients
can be used also to study diseased cells and figure out what is wrong with them
iPSCs are outstanding tools for disease modeling